Last updated: February 24, 2026
What is the drug associated with NDC 70677-0151?
NDC 70677-0151 is associated with Rybelsus (semaglutide), an oral glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management. It was approved in September 2019.
Market Dynamics
Market Size and Growth
The global type 2 diabetes market exceeds USD 50 billion in 2022, with oral GLP-1 receptor agonists like Rybelsus capturing increasing market share. The growth is driven by:
- Rising prevalence of type 2 diabetes, estimated at 537 million worldwide in 2021.
- Preference for oral over injectable therapies, especially among patient populations averse to injections.
- Positive clinical trials demonstrating efficacy in weight management and glycemic control.
Competitive Landscape
Major competitors include:
- Dulaglutide (Trulicity) and Liraglutide (Victoza)—injectable GLP-1 receptor agonists.
- Ozempic (semaglutide injection)—another injectable form.
- Other oral agents such as DPP-4 inhibitors and SGLT2 inhibitors.
Market Share and Trends
- Rybelsus captured approximately 20% of oral GLP-1 market share in 2022.
- Sales totaled USD 1.2 billion in 2022, projected to grow at a CAGR of 20% through 2027.
- Clinical evidence supporting weight loss increases Rybelsus’s appeal compared to earlier injectables.
Price Trends and Projections
Current Price Points
The wholesale acquisition cost (WAC) for Rybelsus varies by dosage:
| Dose (mg) |
Monthly WAC (USD) |
Average Patient Copay (USD) |
| 3 mg |
$840 |
$15-50 |
| 7 mg |
$940 |
$60-80 |
| 14 mg |
$1,200 |
$80-150 |
Prices are consistent across major pharmacy chains, with discounts via pharmacy benefit managers (PBMs).
Price Drivers
- Patent exclusivity extending until at least 2030, limiting generic competition.
- Potential for price increases due to demand, manufacturing costs, and inflation.
- Future biosimilar entry unlikely before 2030, given current patent protections.
Regulatory and Policy Impact
- Pricing pressure from payers and government programs aiming to reduce drug costs.
- Potential negotiations with Medicare and Medicaid may influence net prices for patients.
- Price caps and formulary restrictions could moderate retail costs.
Price Projections (2023-2027)
| Year |
Expected Average Wholesale Price (USD) |
Comments |
| 2023 |
$850 - $1,200 |
Stable, slight fluctuation with inflation. |
| 2024 |
$860 - $1,250 |
Minor increases anticipated to offset manufacturing costs. |
| 2025 |
$880 - $1,300 |
Market expansion may push prices higher. |
| 2026 |
$900 - $1,350 |
Continued inflationary pressures. |
| 2027 |
$920 - $1,400 |
Entry of biosimilars unlikely; market consolidation probable. |
Summary of Key Market and Pricing Insights
- The market for Rybelsus remains robust, with strong growth driven by its oral administration route and clinical benefits.
- Prices are expected to remain relatively stable through 2024, with gradual increases aligned with inflation and demand growth.
- Patent protections delay biosimilar competition, supporting high price levels until at least 2030.
- Payer and policy developments could influence net patient prices, with potential for discounts and formulary restrictions.
Key Takeaways
- NDC 70677-0151 represents Rybelsus, the leading oral GLP-1 RA.
- Market size grows at approximately 20% CAGR, with USD 1.2 billion in sales in 2022.
- Current retail prices range from USD 840 to USD 1,200 monthly, with minimal variation.
- Prices likely to increase gradually until patent expiry, barring policy interventions.
- Biosimilar competition is unlikely before 2030 due to patent protections.
FAQs
1. How does Rybelsus compare in price to injectable GLP-1 receptor agonists?
Injectables like Trulicity and Victoza have similar or higher price points but require injections, influencing patient choice.
2. What factors could reduce the price of Rybelsus in the future?
Biosimilar approvals, government negotiations, and formulary restrictions could lower net prices.
3. Is Rybelsus covered by most insurance plans?
Yes, most commercial and government plans cover Rybelsus, though copay amounts vary.
4. How is the market share of Rybelsus expected to evolve?
It is projected to increase as more patients prefer oral therapy over injections and as clinical evidence expands.
5. When can biosimilars be expected to enter the market?
Potential biosimilar entry is unlikely before 2030 due to current patent protections and market entry barriers.
References
[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] Leerink. (2022). Diabetes Drug Market Outlook.
[3] FDA. (2019). FDA Approval of Rybelsus.
[4] Statista. (2022). Global Diabetes Market Size.
[5] Deloitte. (2022). Pharmaceutical Pricing Trends.
